Business and Finance

Annual Jones Lang LaSalle report ranks US clusters, looks at international activity

Patients, physicians and pharmacists signal their support of copay cards in Alliance Life Sciences study

PwC's annual analysis sees bright spots in R&D practices, while global economic troubles will constrain healthcare spending

Peer-reviewed study correlates adverse drug events (ADEs) with form of drug administration; can pharma manufacturers help?

New study magnifies the lost opportunity for industry eighteen-fold; the global gap is $564 billion

The new insurance exchanges are bound to impact industry rebates - and therefore the ability to manage financial reporting, says PwC Health Research Institute

Understand when total cost of care is the only winning argument - and when you can ignore it, says Oliver Wyman

Implications for pharma are in continuing pricing pressure, and preferences for distribution channels

Action adds to the increasing number of global healthcare-distribution pathways

Although controversial, patient-focused discounts can play a valuable role in managed-markets programs

While 78% of survey respondents will "demand clear proof of cost savings" to ensure formulary placement, 44% of them have "little or no confidence" in the economic arguments presented by pharmacos

Dohmen pioneers an integrated, 'conflict free' pharmaceutical services company

The leading chain pharmacy steps up its role as healthcare provider and partner to pharma

Biopharma remains a bright spot in US and international economic activity, even while the overall outlook remains cloudy

Latest annual Progressions report highlights the shift to healthy behaviors

Patient office visits, prescription usage continued to decline

Covis Pharmaceuticals' business model is to acquire distribution rights to low-volume drugs

Applying a consistent framework to choose locations can help optimize R&D and drive cost reduction for pharmaceutical companies of all sizes

Pharmaceutical Commerce sat down with Chris Smith, president and COO; here's what he had to say.

Buys marketing rights to networks of independent pharmacies for C$920 million

White paper points out the drop in pipeline performance; suggests a new direction is necessary

Taking a market-by-market approach to maximizing value after loss of exclusivity